Can angiotensin-converting enzyme inhibitors protect against symptomatic radiation pneumonitis?

Radiation Research

Volumn 153, Issue 4, 2000, Pages 405-410

  Wang, Ling Wei ^a   Fu, Xiao Long ^a   Clough, Robert ^a   Sibley, Gregory ^a   Fan, Ming ^a   Bentel, Gunilla C ^a   Marks, Lawrence B ^a   Anscher, Mitchell S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENAZEPRIL; CAPTOPRIL; CARBOPLATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ETOPOSIDE; FOSINOPRIL; LISINOPRIL; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; QUINAPRIL;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FEMALE; FOLLOW UP; HUMAN; LUNG CANCER; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIATION PNEUMONIA; TREATMENT OUTCOME;

STAPHYLOCOCCUS PHAGE 187;

EID: 0342369395     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/0033-7587(2000)153[0405:CACEIP]2.0.CO;2     Document Type: Article

References (42)

1. D. Cox, N. Azarnia, R. W. Byhardt, K. H. Shin, B. Emami and T. Pajak, A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with ≥69.6 Gy in favorable patients with radiation therapy oncology group Stage III non-small cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11 J. Clin. Oncol. 8, 1543-1555 (1990).
2. B. Emami, J. Lyman, A. Brown, L. Coia, M. Goitein, J. E. Munzenrider, B. Shank, L. J. Solin and M. Wesson, Tolerance of normal tissue to therapeutic irradiation. Int. J. Radiat. Oncol. Biol. Phys. 21, 109-122 (1991).
3. L. B. Marks, D. P. Spencer, G. C. Bentel, G. W. Sherouse, S. Ray, M. Sontag, R. E. Coleman, R. I. Jaszczak, T. G. Turkington and L. R. Prosnitz, The utility of SPECT lung perfusion scans in minimizing and assessing the physiologic consequences of thoracic irradiation. Int. J. Radiat. Oncol. Biol. Phys. 26, 659-668 (1993).
4. Y. Segawa, N. Takigawa, I. Kataoka, N. Fujimoto and H. Ueoka, Risk factors for development of radiation pneumonitis following radiation therapy with or without chemotherapy for lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 39, 91-98 (1997).
5. M. Graham, J. Purdy, B. Emami, W. Harms, W. Bosch, M. Lockett and C. Perez, Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int. J. Radiat. Oncol. Biol. Phys. 45, 323-329 (1999).
6. M. Martel, R. Ten Haken, M. Hazuka, A. Turrisi, B. Fraas and A. Lichter, Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. Int. J. Radiat. Oncol. Biol. Phys. 28, 575-581 (1994).
7. J. Robertson, R. Ten Haken, M. Hazuka, A. Turrisi, M. Martel, A. Pu, I. Littles, F. Martinez, I. Francis and A. Lichter, Dose escalation for non-small cell lung cancer using conformal radiation therapy. Int. J Radiat. Oncol. Biol. Phys. 37, 1079-1085 (1997).
8. P. Rubin, J. N. Finkelstein and D. Shapiro, Molecular biology mechanisms in the radiation induction of pulmonary injury syndromes: Interrelationship between the alveolar macrophage and the septal fibroblast. Int. J. Radiat. Oncol. Biol. Phys. 24, 93-101 (1992).
9. J. Massague, The transforming growth factor-β family. Anna. Rev. Cell Biol. 6, 597-641 (1990).
10. M. S. Anscher, I. R. Crocker and R. L. Jirtle, Transforming growth factor-β1 expression in irradiated liver. Radiat. Res. 122, 77-85 (1990).
11. M. S. Anscher, W. P. Peters, H. Reisenbichler, W. P. Petros and R. L. Jirtle, Transforming growth factor β as a predictor of liver and lung librosis after autologous bone marrow transplantation for advanced breast cancer. N. Engl. J. Med. 328, 1592-1598 (1993).
12. T. J. Broekelmann, A. H. Limper, T. V. Colby and J. A. McDonald, Transforming growth factor beta-1 is present at sites of extracellular matrix gene expression in human pulmonary tibrosis. Proc. Natl. Acad. Sci. USA 88, 6642-6646 (1991).
13. B. Hoyt and J. Lazo, Alterations in pulmonary mRNA encoding procollagens, fibronectin, and transforming growth factor beta precede bleomycin-induced pulmonary fibrosis. J. Pharmacol. Exp. Ther. 246, 765-771 (1988).
14. B. Hoyt and J. Laso, Early increases in pulmonary mRNA encoding procollagens and transforming growth factor beta in mice sensitive to cyclophosphamide-induced pulmonary fibrosis. J. Pharmacol. Exp. Ther. 249, 38-43 (1989).
15. N. Noble and W. Border. Angiotensin II in renal fibrosis: should TGF-β rather than blood pressure be the target? Semin. Nephrol. 17, 455-466 (1997).
16. W. Ward, A. Moltani, C. Ts'ao and J. Hinz, The effect of captopril on benign and malignant reactions in irradiated rat skin. Br. J. Radiol. 63, 349-354 (1990).
17. R. Shenkar, W. Coulson and E. Abraham, Anti-transforming growth factor-β monoclonal antibodies prevent lung injury in hemorrhagic mice. Am. J. Respir. Cell Mol. Biol. 11, 351-357 (1994).
18. J. Moulder, B. Fish and E. Cohen, Angiotensin II receptor antagonists in the treatment and prevention of radiation nephropathy. Int. J. Radiat. Biol. 73, 415-421 (1998).
19. E. Cohen, A. Molteni, P. Hill, B. Fish, W. Ward, J. Moulder and F. Carone. Captopril preserves function and ultrastructure in experimental radiation nephropathy. Lab Invest. 75, 349-360 (1996).
20. W. Ward, Y. Kim, A. Molteni and N. Solliday, Radiation-induced pulmonary endothelial dysfunction in rats: Modification by inhibitors of angiotensin converting enzyme. Int. J. Radiat. Oncol. Biol. Phys. 15, 135-140 (1988).
21. S. Ali, N. Laping, T. Fredrickson, L. Contino, B. Olson, K. Anderson and D. Brooks, Angiotensin-converting enzyme inhibition attenuates proteinuria and renal TGF-β1 mRNA expression in rats with chronic renal disease. Pharmacology 57, 20-27 (1998).
22. C. Zoja, M. Abbate, D. Coma, M. Capitanio, R. Donadelli, I. Bruzzi, S. Oldroyd, A. Benigni and G. Remuzzi, Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-β in experimental mesangioproliferative glomerulonephritis. Am. J. Kidney Dis. 31, 453-463 (1998).
23. E. L. Kaplan and P. Meier, Nonparametric estimations from incomplete observations. J.Am. Stat. Assoc. 53, 457-481 (1958).
24. W. Ward, A. Molteni and C. Ts'ao, Radiation-induced endothelial dysfunction and fibrosis in rat lung: Modification by the angiotensin converting enzyme inhibitor CL242817. Radiat. Res. 117, 342-350 (1989).
25. W. Ward, A. Molteni, Y. Kim and C. Ts'ao, Structure-function analysis of angiotensin-converting enzyme inhibitors as modifiers of radiation-induced pulmonary endothelial dysfunction in rats. Br. J. Radiol. 62, 348-354 (1989).
26. J. Moulder, B. Fish and E. Cohen, Radiation nephropathy is treatable with an angiotensin converting enzyme inhibitor or an angiotensin II type 1 (AT1) receptor antagonist. Radiother. Oncol. 46, 307-315 (1998).
27. S. Yoon, J. Park, H. Jang, K. Shinn and Y. Bank, Radioprotective effect of captopril on the mouse jejunal mucosa. Int. J. Radiat. Oncol. Biol. Phys. 30, 873-878 (1994).
28. S. Kagami, W. Border, D. Miller and N. Noble, Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J. Clin. Invest. 90, 1-7 (1992).
29. A. Roberts and M. Sporn, The transforming growth factor β's. In Peptide Growth Factors and Their Receptors, pp. 419-472. Springer-Verlag, Berlin, 1990.
30. P. Rubin, C. J. Johnston, I. P. Williams, S. McDonald and J. N. Finkelstein, A perpetual cascade of cytokines post irradiation leads to pulmonary ribrosis. Int. J. Radiat. Oncol. Biol. Phys. 33, 99-109 (1995).
31. M. H. Barcellos-Hoff, R. Derynck, M. L-S. Psang and I. A. Weatherbee, Transforming growth factor beta activation in irradiated murine mammary gland. J. Clin. Invest. 93, 892-899 (1994).
32. A. Castilla, J. Prieto and N. Fausto, Transforming growth factors beta-1 and alpha in chronic liver disease - effects of interferon alpha therapy. N. Eng. J. Med. 324, 993-940 (1991).
33. P. Datta, J. Moulder, B. Fish, E. Cohen and E. Lianos, TGF-β1 production in radiation nephropathy: Role of angiotensin II. Int. J. Radiat Biol. 75, 473-479 (1999).
34. Capoten Tablets. Physician's Desk Reference, Vol. 57, pp. 740-744. Medical Economics Company, Montvale, NJ, 1997.
35. F-M. Kong, M. K. Washington, R. L. Jirtle and M. S. Anscher, Plasma transforming growth factor β1 reflects disease status in patients with lung cancer after radiotherapy: A possible tumor marker. Lung Cancer 16, 47-59 (1996).
36. M. H. Barcellos-Hoff and T. Dix, Redox-mediated activation of latent transforming growth factor-β1. Mol. Endocrinol. 10, 1077-1083 (1996).
37. M. S. Anscher, F-M. Kong, T. Murase and R. L. Jirtle, Normal tissue injury after cancer therapy is a local manifestation of a systemic condition. Br. J. Radiol. 68, 331-333 (1995).
38. F. M. Kong, M. S. Anscher, B. Abbott, T. Murase, J. D. Iglehart and R. L. Jirtle, Elevated plasma TGFβ1 levels in breast cancer patients decrease following removal of the tumor. Ann. Surg. 222, 155-162 (1995).
39. J. J. Letterio, A. G. Geiser, A. B. Kulkarni, N. S. Roche, M. B. Sporn and A. B. Roberts, Maternal rescue of transforming growth factor-β1 null mice. Science 264, 1936-1938 (1994).
40. T. Fynan and M. Reiss. Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit. Rev. Oncogen. 4, 493-540 (1993).
41. J. Benson, H. Poulsen, S. Hougaard and P. Norgaard, TGFβ and cancer in other organs. Lung cancer. In TGFβ and Cancer (J. Benson, Ed.), pp. 155-158. R. G. Landes, London, 1998.
42. P. Dennis and D. Rifkin, Cellular activation of latent transforming growth factor β requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc. Natl. Acad. Sci. USA 88, 580-584 (1991).